Immunotherapy Vaccine and Herceptin in Breast Cancer

Phase Ib Trial of Combination Immunotherapy With HER2/Neu Peptide GP2 + GM-CSF Vaccine and Trastuzumab in Breast Cancer Patients

The purpose of this trial is to determine if combination immunotherapy with HER2/neu GP2 peptide + GM-CSF vaccine and trastuzumab is safe and immunologically effective in treatment of patients with HER2/neu over-expressing breast cancer in the adjuvant setting. While not a primary endpoint, time to recurrence is measured for enrolled subjects. The objectives of the study are the following:

• Assess safety and document local and systemic toxicity to combination immunotherapy with GP2 peptide + GM-CSF vaccine and trastuzumab
• Evaluate the in vitro and in vivo immunologic responses to combination immunotherapy of GP2 peptide + GM-CSF vaccine and trastuzumab
• Determine maximum tolerated dose and optimal biologic dose for the combination immunotherapy of GP2 peptide + GM-CSF vaccine and trastuzumab

Study Overview

• Status: Completed
• Conditions: Breastcancer
• Intervention / Treatment: Drug: GP2 peptide + GM-CSF vaccine plus trastuzumab; Drug: Trastuzumab

• Study Type: Interventional
• Enrollment (Actual): 30
• Phase: Phase 1

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: Female

Description

Inclusion Criteria:

• Age > 18 years
• HER2/neu+ over-expressing breast cancer (IHC 3+ or FISH ≥2.0)
• Patients who are receiving adjuvant trastuzumab as standard of care treatment
• Completion of breast cancer therapy (i.e., surgery, radiation, and chemotherapy as appropriate per standard of care for patients' specific cancer) to exclude trastuzumab (Patients on oral hormonal therapy as part of their adjuvant breast cancer treatment will be maintained on their regimens.)
• Enrollment must occur so that patients' trastuzumab treatment and vaccine schedule overlap for all 6 vaccinations and so that first vaccination occurs after a standard of care Multiple Gated Acquisition Scan (MUGA)
• ECOG performance status (PS) 0-1
• Clinically cancer-free (no evidence of disease; excluding +CTC)
• If the patient is of childbearing potential, she must be willing to practice adequate contraception through the study treatment period and for 2 months after completion of the injection sites
• Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria:

• Clinical and/or radiographic evidence of residual or persistent breast cancer
• Receiving immunosuppressive therapy to include methotrexate or steroids (note: the use of prednisone, or equivalent, <2.0mg/day, is allowed)
• Tbili >1.8, creatinin >2, hemoglobin <10, platelets <100,000/mm³, WBC <2,000
• Active pulmonary disease requiring medication to include multiple inhalers
• Patients may not be receiving any other investigational agents (except with permission of the Lead Principal Investigator)
• Pregnant or are nursing
• History of autoimmune disease (patients with vitiligo not excluded)
• HIV positive
• Previous or concomitant malignancies at other sites, except effectively treated non- melanoma skin cancers or carcinoma in situ of the cervix or effectively treated malignancy that has been in remission for over 5 years and highly likely to have been cured
• Other concurrent severe medical problems, unrelated to the malignancy, that would significantly limit full compliance with the study or expose the patient to unacceptable risk
• Uncontrolled congestive heart failure or hypertension, unstable heart disease (coronary artery disease or myocardial infarction) or uncontrolled arrhythmia at the time of enrollment
• Psychiatric, addictive, or any disorder which compromises ability to give truly informed consent for participation in this study or adequate compliance

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: GP2 peptide + GM-CSF + trastuzumab; HLA-A2+/A3+ subjects receive GP2 + GM-CSF vaccine and trastzumab	Drug: GP2 peptide + GM-CSF vaccine plus trastuzumab; HLA-A2+/A3+ subjects are given the GP2 peptide vaccine plus trastuzumab
Active Comparator: Trastuzumab; HLA-A2-/A3- subjects followed as controls receiving trastuzumab.	Drug: Trastuzumab; HLA-A2-/A3- patients are followed as controls receiving trastuzumab only.; Other Names: Herceptin

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Treatment-Related Adverse Events as Assessed by CTCAE v4.0	Patients receiving treatment will be followed from baseline to completion of study for adverse events using CTCAE v4.0	12 months

Collaborators and Investigators

• Sponsor: Cancer Insight, LLC
• Investigators: Principal Investigator: George E Peoples, MD, Cancer Insight

Study record dates

Study Major Dates

• Study Start: January 1, 2008
• Primary Completion (Actual): January 1, 2016
• Study Completion (Actual): January 1, 2017

Study Registration Dates

• First Submitted: January 4, 2017
• First Submitted That Met QC Criteria: January 6, 2017
• First Posted (Estimate): January 9, 2017

Study Record Updates

• Last Update Posted (Estimate): January 9, 2017
• Last Update Submitted That Met QC Criteria: January 6, 2017
• Last Verified: January 1, 2017

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Skin Diseases; Neoplasms; Neoplasms by Site; Breast Diseases; Breast Neoplasms; Antineoplastic Agents; Antineoplastic Agents, Immunological; Trastuzumab
• Other Study ID Numbers: C.2008.146

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No